AU2933997A - Therapies for chronic renal failure - Google Patents

Therapies for chronic renal failure

Info

Publication number
AU2933997A
AU2933997A AU29339/97A AU2933997A AU2933997A AU 2933997 A AU2933997 A AU 2933997A AU 29339/97 A AU29339/97 A AU 29339/97A AU 2933997 A AU2933997 A AU 2933997A AU 2933997 A AU2933997 A AU 2933997A
Authority
AU
Australia
Prior art keywords
renal failure
chronic renal
therapies
risk
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU29339/97A
Other languages
English (en)
Inventor
Charles M. Cohen
Kuber T. Sampath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creative Biomolecules Inc
Original Assignee
Creative Biomolecules Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc filed Critical Creative Biomolecules Inc
Priority to AU29339/97A priority Critical patent/AU2933997A/en
Publication of AU2933997A publication Critical patent/AU2933997A/en
Priority to AU71419/00A priority patent/AU757969B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU29339/97A 1996-05-06 1997-05-06 Therapies for chronic renal failure Abandoned AU2933997A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU29339/97A AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
AU71419/00A AU757969B2 (en) 1996-05-06 2000-11-03 Therapies for chronic renal failure

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08643321 1996-05-06
US08/643,321 US6498142B1 (en) 1996-05-06 1996-05-06 Morphogen treatment for chronic renal failure
AU29339/97A AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure
PCT/US1997/007655 WO1997041880A1 (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU71419/00A Division AU757969B2 (en) 1996-05-06 2000-11-03 Therapies for chronic renal failure

Publications (1)

Publication Number Publication Date
AU2933997A true AU2933997A (en) 1997-11-26

Family

ID=24580305

Family Applications (2)

Application Number Title Priority Date Filing Date
AU28322/97A Abandoned AU2832297A (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure
AU29339/97A Abandoned AU2933997A (en) 1996-05-06 1997-05-06 Therapies for chronic renal failure

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU28322/97A Abandoned AU2832297A (en) 1996-05-06 1997-05-06 Morphogen treatment for chronic renal failure

Country Status (11)

Country Link
US (5) US6498142B1 (enExample)
EP (2) EP0914146B1 (enExample)
JP (4) JP2000510835A (enExample)
AT (2) ATE277629T1 (enExample)
AU (2) AU2832297A (enExample)
CA (2) CA2254954C (enExample)
DE (2) DE69723845T2 (enExample)
DK (2) DK0910400T3 (enExample)
ES (2) ES2203803T3 (enExample)
PT (2) PT910400E (enExample)
WO (2) WO1997041880A1 (enExample)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104678C (en) * 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US20030167492A1 (en) 1994-07-08 2003-09-04 Johns Hopkins University School Of Medicine Transgenic non-human animals expressing a gdf-11 dominant negative polypeptide, and methods of making and using same
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
DK0980252T3 (da) * 1997-05-05 2005-01-31 Curis Inc Terapier til akut nyresvigt
WO1998050061A1 (en) * 1997-05-07 1998-11-12 Biogen, Inc. Novel therapies for cystic kidney disease
DE69714035T2 (de) 1997-08-14 2003-03-06 Sulzer Innotec Ag, Winterthur Zusammensetzung und Vorrichtung zur Reparatur von Knorpelgewebe in vivo bestehend aus Nanokapseln mit osteoinduktiven und/oder chondroinduktiven Faktoren
US6203788B1 (en) * 1997-09-29 2001-03-20 Adherex Inc. Compounds and methods for regulating cell adhesion
WO1999028341A2 (en) * 1997-12-04 1999-06-10 Creative Biomolecules, Inc. Maintenance of smooth muscle integrity by morphogenic proteins
NZ528341A (en) * 1998-07-28 2005-06-24 Univ Johns Hopkins Med Use of reagents that affect growth differentiation factor-11 (GDF-11) to treat chronic or acute renal disease
US6992066B2 (en) 1998-10-16 2006-01-31 Zimmer Orthobiologics, Inc. Povidone-containing carriers for polypeptide growth factors
US7087577B2 (en) * 1998-10-16 2006-08-08 Zimmer Orthobiologies, Inc. Method of promoting natural bypass
JP4975922B2 (ja) * 1999-09-14 2012-07-11 バイオジェン・アイデック・エムエイ・インコーポレイテッド １つ以上のインテグリンアンタゴニストを使用する慢性腎不全の治療
US20020173453A1 (en) * 2000-12-15 2002-11-21 Rama Akella Method of treating renal injury
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US7763769B2 (en) 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7232802B2 (en) * 2001-12-21 2007-06-19 Zimmer Orthobiologics, Inc. Compositions and methods for promoting myocardial and peripheral angiogenesis
US7622562B2 (en) 2002-06-26 2009-11-24 Zimmer Orthobiologics, Inc. Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
JP2006516020A (ja) * 2002-08-28 2006-06-15 キュリス インコーポレイテッド 慢性腎不全の治療におけるモルフォゲン及びａｃｅ阻害薬の共投与
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
US7844367B2 (en) 2003-12-23 2010-11-30 Rain Bird Corporation Code replacement for irrigation controllers
PL1732523T3 (pl) * 2004-03-30 2010-08-31 Vifor Pharma Tech Ltd Polimery wiążące potas i ich zastosowania
EP1730186A2 (en) * 2004-03-31 2006-12-13 Xencor, Inc. Bmp-7 variants with improved properties
US20100150885A1 (en) * 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
US7598364B2 (en) * 2005-11-14 2009-10-06 Merial Limited Plasmid encoding canine BMP-7
US7771995B2 (en) * 2005-11-14 2010-08-10 Merial Limited Plasmid encoding human BMP-7
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
JP2009524436A (ja) 2006-01-24 2009-07-02 ノースフィールド ラボラトリーズ、インコーポレイテッド 重合したヘモグロビンの培地、並びに島細胞の単離及び移植におけるその使用
US20080090765A1 (en) * 2006-05-25 2008-04-17 The Trustees Of Columbia University In The City Of New York Compositions for modulating growth of embryonic and adult kidney tissue and uses for treating kidney damage
ATE539351T1 (de) 2006-05-30 2012-01-15 Antibodyshop As Verfahren zur schnellen beurteilung der schwere eines traumas
US7722665B2 (en) * 2006-07-07 2010-05-25 Graft Technologies, Inc. System and method for providing a graft in a vascular environment
JP5175729B2 (ja) 2006-07-21 2013-04-03 中外製薬株式会社 腎疾患治療剤
CA2672560A1 (en) * 2006-12-15 2008-06-26 Ruprecht-Karls-Universitaet Heidelberg Methods for treating podocyte-related disorders
EP2148706A2 (en) * 2007-04-24 2010-02-03 Advanced Technologies and Regenerative Medicine, LLC Engineered renal tissue
DE102007034580B4 (de) * 2007-07-13 2012-11-08 NMI Naturwissenschaftliches und Medizinisches Institut an der Universität Tübingen Biomaterial basierend auf einem hydrophilen polymeren Träger
US20090155245A1 (en) * 2007-12-18 2009-06-18 Fang Carrie H Treatment for Organ Regeneration with Combination of Drug and Biologics
AU2009244308A1 (en) * 2008-05-06 2009-11-12 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
JP5485885B2 (ja) * 2008-06-24 2014-05-07 株式会社根本杏林堂 薬液注入装置、この薬液注入装置を有する透視撮像システム、薬液注入装置のコンピュータプログラムおよびデータ処理方法
BRPI0917711A2 (pt) * 2008-08-28 2017-06-20 Astute Medical Inc método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
JP5947544B2 (ja) * 2008-08-29 2016-07-06 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法および組成物
WO2010048346A1 (en) * 2008-10-21 2010-04-29 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2009308375B2 (en) * 2008-10-21 2015-06-25 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
EP2913676A1 (en) 2008-11-10 2015-09-02 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP5735922B2 (ja) * 2008-11-22 2015-06-17 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後のための方法
CN106546752A (zh) * 2009-02-06 2017-03-29 阿斯图特医药公司 肾损伤和肾衰竭的诊断及预后
US9229010B2 (en) 2009-02-06 2016-01-05 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
CN102369016A (zh) * 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用
AU2010213591B2 (en) * 2009-02-12 2013-11-21 Stryker Corporation Compositions and methods for minimally-invasive systemic delivery of proteins including TGF-beta superfamily members
WO2010103070A2 (en) 2009-03-12 2010-09-16 Charité - Universitätsmedizin Berlin Bone morphogenetic protein 2 (bmp2) variants with reduced bmp antagonist sensitivity
WO2010144696A1 (en) 2009-06-11 2010-12-16 Burnham Institute For Medical Research Directed differentiation of stem cells
JP5827226B2 (ja) 2009-08-07 2015-12-02 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011035094A1 (en) 2009-09-17 2011-03-24 Stryker Corporation Buffers for controlling the ph of bone morphogenetic proteins
NZ628085A (en) 2009-11-07 2015-12-24 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
ES2818138T3 (es) 2009-12-20 2021-04-09 Astute Medical Inc Métodos y composiciones para el diagnóstico y pronóstico de lesión renal e insuficiencia renal
CA2785038A1 (en) 2009-12-22 2011-07-21 Stryker Corporation Bmp-7 variants with reduced immunogenicity
EP2666872B1 (en) 2010-02-05 2016-04-27 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
WO2011106746A1 (en) 2010-02-26 2011-09-01 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
JP2013529907A (ja) 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
EP2585827A4 (en) 2010-06-23 2013-12-04 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
EP2585825B1 (en) 2010-06-23 2018-01-10 Astute Medical, Inc. Methods and compositions for diagnosis and prognosis of renal injury and renal failure
AU2011292810B2 (en) 2010-08-20 2015-04-30 Wyeth Llc Designer osteogenic proteins
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
EP3540440B1 (en) 2011-12-08 2022-09-28 Astute Medical, Inc. Methods and uses for evaluating renal injury and renal status
CN119405686A (zh) 2012-10-08 2025-02-11 维福(国际)有限公司 治疗高血压和高血钾症的钾结合剂
WO2014081980A2 (en) 2012-11-21 2014-05-30 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
JP6681195B2 (ja) 2013-01-17 2020-04-15 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
US9169308B2 (en) 2013-01-25 2015-10-27 Warsaw Orthopedic, Inc. Methods and compositions of human recombinant growth and differentiation factor-5 (rhGDF-5) isolated from inclusion bodies
US8945872B2 (en) 2013-01-25 2015-02-03 Warsaw Orthopedic, Inc. Methods of purifying human recombinant growth and differentiation factor-5 (rhGDF-5) protein
US9359417B2 (en) 2013-01-25 2016-06-07 Warsaw Orthopedic, Inc. Cell cultures and methods of human recombinant growth and differentiaton factor-5 (rhGDF-5)
US8956829B2 (en) 2013-01-25 2015-02-17 Warsaw Orthopedic, Inc. Human recombinant growth and differentiaton factor-5 (rhGDF-5)
US9051389B2 (en) 2013-01-25 2015-06-09 Warsaw Orthopedic, Inc. Expression conditions and methods of human recombinant growth and differentiation factor-5 (rhGDF-5)
EP2784083A1 (en) 2013-03-28 2014-10-01 Charité - Universitätsmedizin Berlin Bone Morphogenetic Protein (BMP) variants with highly reduced antagonist sensitivity and enhanced specific biological activity
JP2016536588A (ja) * 2013-11-11 2016-11-24 ゼネラル・エレクトリック・カンパニイ ロータ速度の測定における誤差を低減する方法
EP2944326B1 (en) 2014-05-16 2018-11-21 Cyanagen Srl Tricarbocyanine-cyclodextrin-conjugates and their use for the diagnosis of kidney diseases
US11241505B2 (en) 2015-02-13 2022-02-08 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
EP3465201A4 (en) 2016-06-06 2020-08-26 Astute Medical, Inc. MANAGEMENT OF ACUTE KIDNEY DAMAGE USING INSULINOMIMETIC GROWTH FACTOR BINDING PROTEIN 7 AND TISSUE METALLOPROTEINASE 2 INHIBITOR
US10576167B2 (en) 2016-08-17 2020-03-03 Factor Bioscience Inc. Nucleic acid products and methods of administration thereof
JP2019039673A (ja) * 2017-08-22 2019-03-14 セイコーエプソン株式会社 時間デジタル変換回路、回路装置、物理量測定装置、電子機器及び移動体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1156741B (it) * 1978-05-15 1987-02-04 Sigma Tau Ind Farmaceuti Applicazione terapeutica della carnitina e di alcuni derivati acilati della carnitina nell'emodialisi
US4342828A (en) 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4627839A (en) 1985-11-21 1986-12-09 American Hospital Supply Corporation Patient controlled analgesia conversion
IL83003A (en) 1986-07-01 1995-07-31 Genetics Inst Osteoinductive factors
US5013649A (en) 1986-07-01 1991-05-07 Genetics Institute, Inc. DNA sequences encoding osteoinductive products
US5011691A (en) 1988-08-15 1991-04-30 Stryker Corporation Osteogenic devices
US5266683A (en) 1988-04-08 1993-11-30 Stryker Corporation Osteogenic proteins
US5045452A (en) 1988-09-02 1991-09-03 Brigham And Women's Hospital Method for evaluating nephrotoxicity
EP0429570B1 (en) 1989-03-28 1998-01-14 Genetics Institute, Inc. Osteoinductive compositions
ATE209251T1 (de) 1990-05-16 2001-12-15 Genetics Inst Knochen- und knorpel-bildung hervorrufende proteine
JPH0426624A (ja) * 1990-05-18 1992-01-29 Tsumura & Co 慢性腎不全改善剤
ATE146076T1 (de) * 1990-06-22 1996-12-15 Du Pont Behandlung des chronischen nierenversagens mit imidazol-angiotensin-ii-rezeptorantagonisten
US6194376B1 (en) 1991-03-11 2001-02-27 Creative Biomolecules, Inc. Method for modulating inflammatory response comprising administering morphogen
US6077823A (en) * 1991-03-11 2000-06-20 Creative Biomolecules, Inc. Method for reducing tissue damage associated with ischemia-reperfusion or hypoxia injury
US5849686A (en) * 1991-03-11 1998-12-15 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
JP3627985B2 (ja) 1991-03-11 2005-03-09 キュリス インコーポレイテッド タンパク質により誘導される形態形成
CA2104678C (en) 1991-03-11 2002-05-14 Charles M. Cohen Protein-induced morphogenesis
US7056882B2 (en) 1991-03-11 2006-06-06 Curis, Inc. Treatment to prevent loss of and/or increase bone mass in metabolic bone diseases
US6287816B1 (en) 1991-06-25 2001-09-11 Genetics Institute, Inc. BMP-9 compositions
JP3616089B2 (ja) 1991-08-30 2005-02-02 キュリス インコーポレイテッド 形態形成誘導蛋白のスクリーニング方法
ES2149776T5 (es) 1991-08-30 2004-07-01 Curis, Inc. Modulacion, inducida por un morfogeno, de la respuesta inflamatoria.
ATE308336T1 (de) 1991-08-30 2005-11-15 Curis Inc Osteogenische proteine in der behandlung von metabolischen knochenkrankheiten
US6120760A (en) * 1992-02-12 2000-09-19 Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Growth/differentiation factors of the TGF-β family
AU681594B2 (en) 1992-07-31 1997-09-04 Stryker Corporation Morphogen-induced nerve regeneration and repair
JP3981405B2 (ja) 1992-07-31 2007-09-26 ストライカー・コーポレーション 形態形成蛋白質溶解型複合体，及びその組成
WO1994003075A2 (en) 1992-07-31 1994-02-17 Creative Biomolecules, Inc. Morphogen-enriched dietary composition
EP0661987B1 (en) 1992-09-16 1998-01-14 Creative Biomolecules, Inc. Morphogen-induced liver regeneration
JPH08503198A (ja) 1992-11-03 1996-04-09 クリエイティブ バイオモレキュルズ，インコーポレイテッド Ｏｐ−３誘導形態形成
US5372335A (en) 1992-12-18 1994-12-13 Scott H. Yenzer Aerial marker ball and method of placement
AU682176B2 (en) 1993-03-04 1997-09-25 Stryker Corporation Method and compositions for recombinant osteogenic protein production
US5631159A (en) 1993-09-22 1997-05-20 Creative Biomolecules, Inc. Lipid-modified serum free media
US5585237A (en) 1993-10-25 1996-12-17 Creative Biomolecules, Inc. Methods and compositions for high protein production from recombinant DNA
ATE225666T1 (de) * 1993-11-15 2002-10-15 Celtrix Pharma Verwendung von igf-1 und igfbp-3 zur herstellung eines arzneimittels zur behandlung von einer nierenerkrankung
US5525621A (en) * 1994-05-20 1996-06-11 Cytos Pharmaceuticals Llc Imidazole derivatives as protective agents in reperfusion injury and severe inflammatory responses
US5714511A (en) 1995-07-31 1998-02-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs
US5723411A (en) * 1995-10-31 1998-03-03 E. I. Du Pont De Nemours And Company Herbicidal pyridazinones
US6214796B1 (en) 1996-03-22 2001-04-10 The General Hospital Corporation Administration of polypeptide growth factors following central nervous system ischemia or trauma
US5820589A (en) 1996-04-30 1998-10-13 Medtronic, Inc. Implantable non-invasive rate-adjustable pump
US6498142B1 (en) 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
US5879908A (en) * 1997-04-30 1999-03-09 Smithkline Beecham Corporation CRFG-1a, a target and marker for chronic renal failure
US7147839B2 (en) * 1998-05-29 2006-12-12 Curis, Inc. Methods for evaluating tissue morphogenesis and activity

Also Published As

Publication number Publication date
ATE277629T1 (de) 2004-10-15
US8377878B2 (en) 2013-02-19
US7524817B2 (en) 2009-04-28
JP4766722B2 (ja) 2011-09-07
CA2254954A1 (en) 1997-11-13
CA2254954C (en) 2010-01-12
US6498142B1 (en) 2002-12-24
JP2009185076A (ja) 2009-08-20
EP0910400A1 (en) 1999-04-28
DK0914146T3 (da) 2005-01-31
PT914146E (pt) 2005-02-28
DK0910400T3 (da) 2003-11-24
DE69730966T2 (de) 2006-02-23
ES2230604T3 (es) 2005-05-01
WO1997041880A1 (en) 1997-11-13
EP0910400B1 (en) 2003-07-30
EP0914146B1 (en) 2004-09-29
CA2254953A1 (en) 1997-11-13
DE69723845D1 (de) 2003-09-04
US20100291170A1 (en) 2010-11-18
EP0914146A1 (en) 1999-05-12
US20120004171A1 (en) 2012-01-05
JP2000510124A (ja) 2000-08-08
JP5247593B2 (ja) 2013-07-24
JP2012229268A (ja) 2012-11-22
ATE245997T1 (de) 2003-08-15
PT910400E (pt) 2003-12-31
AU2832297A (en) 1997-11-26
US20050143304A1 (en) 2005-06-30
DE69730966D1 (de) 2004-11-04
DE69723845T2 (de) 2004-06-03
CA2254953C (en) 2006-09-26
US6861404B1 (en) 2005-03-01
WO1997041881A1 (en) 1997-11-13
US8017580B2 (en) 2011-09-13
ES2203803T3 (es) 2004-04-16
JP2000510835A (ja) 2000-08-22

Similar Documents

Publication Publication Date Title
AU2933997A (en) Therapies for chronic renal failure
WO1998033509A3 (en) Useful properties of human lactoferrin and variants thereof
AU6889896A (en) Syringe serving also as an ampule and syringe for collecting blood
FI960809A7 (fi) Hermoregeneraatio käyttäen ihmisen luun morfogeneettisiä proteiineja
EP0212474A3 (en) Bone morphogenetic peptides
DE69432582D1 (de) System zur Administration von Flüssigkeiten bei mehreren Patienten
MXPA03011386A (es) Proteina de union para su uso en la regeneracion de hueso o cartilago.
AU3866097A (en) Naphtholactams and lactones as bone morphogenetic protein active agents
WO2000020449A3 (en) MODIFIED TGF-β SUPERFAMILY PROTEINS
NO982436D0 (no) Apparat for oppvarming av blod
SG1893G (en) Biologically active fragments of the human antihemophilic factor and method for their preparation and pharmaceutical preparations
AU8073498A (en) Liquid delivery system, heater apparatus for liquid delivery system, and vaporizer
EP0766974A3 (en) Blood reservoir, blood delivery instrument, and blood delivery apparatus
DK0980252T3 (da) Terapier til akut nyresvigt
AU3909497A (en) Anti-chlamydial methods and materials
WO2004019876A3 (en) Conjoint administration of morphogens and ace inhibitors in treatment of chronic renal failure
DE69714451D1 (de) Prionbindende proteine und deren verwendungen
EP1169058A4 (en) INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-4 Protease
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
AU2242897A (en) Protein occlusion for delivery of small molecules
BR9713514A (pt) Novo uso de creatina
ZA966577B (en) Pharmaceutical composition.
ATE222479T1 (de) Einheit zur knorpelreparatur
FR2729074B1 (fr) Ecrou taraude autofreinant pour l'assemblage d'appareillages de chirurgie reconstructive, notamment en osteosynthese rachidienne
PT999849E (pt) Utilizacao de lbp no tratamento da septicemia

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted